Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

Active, not recruitingOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Postural Orthostatic Tachycardia SyndromeAcute Hepatic Porphyria
Interventions
DIAGNOSTIC_TEST

Autonomic Function Testing

Autonomic function test (orthostatic blood pressure and heart rate response to tilt, heart rate response to deep breathing, the Valsalva ratio, and beat-to-beat blood pressure measurements during phases II and IV of the Valsalva maneuver, tilt, and deep breathing). These combined tests provide a measurement of adrenergic, cardiovagal responses.

DIAGNOSTIC_TEST

Genetic Testing

Genetic testing: for Acute hepatic porphyria panel - with intent to use Saliva kit

DIAGNOSTIC_TEST

Urine Testing

Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine

DIAGNOSTIC_TEST

Blood laboratory Testing

"To determine the following laboratory analyses:~CBC, CMP, Iron studies (Ferritin and iron studies)"

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER